In a recent article, we examined the regulatory, litigation, and compliance developments surrounding GLP-1 therapies. As these medications have become more widely used, discussions across healthcare, research, and industry have expanded beyond their original role in diabetes treatment and weight management.

For decades, antibiotics have been one of modern medicine's greatest success stories. They transformed once-deadly infections into treatable conditions, making routine surgeries, organ transplants, cancer therapies, and intensive care medicine possible. But a growing threat is challenging that foundation: antimicrobial resistance (AMR).

On August 3, 2026, the California Supreme Court issued its decision in the Gilead Tenofovir Cases, rejecting a novel negligence theory that would have significantly expanded potential liability for pharmaceutical manufacturers. The ruling reverses a California Court of Appeal decision that had recognized what many have described as a "duty to innovate," a theory that would have permitted plaintiffs to pursue negligence claims based not on defects in an existing product, but rather on allegations that a manufacturer delayed bringing a safer alternative product to market.